Colorectal cancer: prevention and management of metastatic disease

Paul H Sugarbaker, Paul H Sugarbaker

Abstract

This paper compared the similarities and differences of the two most common types of colorectal cancer metastases. The treatment of liver metastases by surgery combined with systemic chemotherapy was explained. The different natural history of liver metastases as compared to peritoneal metastases and the possibility for prevention of peritoneal metastases were emphasized. Perioperative cancer chemotherapy or second-look surgery must be considered as individualized treatments of selected patients who have small volume peritoneal metastases or who are known to be at risk for subsequent disease progression on peritoneal surfaces. However, the fact that peritoneal metastases, when diagnosed in the follow-up of colorectal cancer patients, can be cured with a combination of cytoreductive surgery and hyperthermic perioperative chemotherapy cannot be ignored. Careful follow-up and timely intervention in colorectal cancer patients with progressive disease are a necessary part of the management strategies recommended by the multidisciplinary team. After a critical evaluation of the data currently available, these strategies for prevention and management of colorectal metastases are presented as the author's recommendations for a high standard of care. As more information becomes available, modifications may be necessary.

Figures

Figure 1
Figure 1
Schematic diagram that presents a theoretical model comparing the progression of one colorectal liver metastasis to one peritoneal metastasis over one year. The liver metastasis will expand within the liver parenchyma with a doubling time of approximately three months. The peritoneal metastasis will progress at approximately the same speed but will also exfoliate cancer cells into the free peritoneal space. Many cancer nodules of many different sizes will occur, widely distributed throughout the abdomen and pelvis within one year (reprinted with permission from Sugarbaker PH. Cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer: a new standard of care or an experimental approach? Gastroenterol Res Pract Volume 2012; 2012: Article ID 309417, 9 pages).
Figure 2
Figure 2
Anatomic sites of right colon cancer progression by the dissemination of cancer cells or minute nodules. The mechanism for right colon cancer implantation and progression at the cancer resection site along the superior mesenteric vessels or on peritoneal surfaces is similar (reprinted with permission from Sugarbaker PH, Sammartino P, and Tentes AA. Proactive management of peritoneal metastases from colorectal cancer: the next logical step toward optimal locoregional control. Colorect Ca 2012; 1 : 115–123).

References

    1. Havelaar IJ, Sugarbaker PH, Vermess M, Miller DL. Rate of growth of intraabdominal metastases from colorectal cancer. Cancer. 1984;54(1):163–171.
    1. Weiss L. Principles of Metastasis. Orlando, Fla, USA: Academic Press; 1985.
    1. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nature Reviews Cancer. 2009;9(4):239–252.
    1. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Annals of Surgery. 2004;240(4):644–657.
    1. Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. Journal of Surgical Oncology. 2010;102(6):576–581.
    1. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbeck’s Archives of Surgery. 1999;384(6):576–587.
    1. Laffer U, Metzger U, Aeberhard P, et al. Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial. International Journal of Colorectal Disease. 2008;23(12):1233–1241.
    1. Quirke P, Sebag-Montefiore D, Steele R, et al. Local recurrence after rectal cancer resection is strongly related to the plane of the surgical dissection and is further reduced by pre-operative short course radiotherapy. Preliminary results of the Medical Research Council (MRC) CR07 trial. Journal of Clinical Oncology. 2006;24, article 3512
    1. Heald RJ, Ryall RDH. Recurrence and survival after total mesorectal excision for rectal cancer. The Lancet. 1986;1(8496):1479–1482.
    1. Birgisson H, Talbäck M, Gunnarsson U, Påhlman L, Glimelius B. Improved survival in cancer of the colon and rectum in Sweden. European Journal of Surgical Oncology. 2005;31(8):845–853.
    1. West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. Journal of Clinical Oncology. 2010;28(2):272–278.
    1. Wilson SM, Adson MA. Surgical treatment of hepatic metastases from colorectal cancers. Archives of Surgery. 1976;111(4):330–334.
    1. Foster JH, Berman MM. Solid Liver Tumors. Philadelphia, Pa, USA: WB Saunders; 1977.
    1. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery. 1986;100(2):278–288.
    1. Kaido T. Verification of evidence in surgical treatment for colorectal liver metastasis. Hepato-Gastroenterology. 2008;55(82-83):378–380.
    1. Fernandez-Trigo V, Shamsa F, Sugarbaker PH, et al. Repeat liver resections from colorectal metastasis. Surgery. 1995;117(3):296–304.
    1. Antoniou A, Lovegrove RE, Tilney HS, et al. Meta-analysis of clinical outcome after first and second liver resection for colorectal metastases. Surgery. 2007;141(1):9–18.
    1. Alexander HR, Jr., Berlin J, Moeslein F. Metastatic cancer to the liver. In: deVita VT Jr., Lawrence TS, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 9th edition. Philadelphia: Lippincott Williams & Wilkins; 2011. pp. 2177–2191.
    1. Honore C, Goere D, Souadka A, Dumont F, Elias D. Definition of patient presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Annals of Surgical Oncology. 2013;20(1):183–192.
    1. Cunliffe WJ, Sugarbaker PH. Gastrointestinal malignancy: Rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. British Journal of Surgery. 1989;76(10):1082–1090.
    1. Sugarbaker PH, Graves T, DeBruijn EA, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Research. 1990;50(18):5790–5794.
    1. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemotherapy and Pharmacology. 1999;43:S15–S25.
    1. Jacquet P, Averbach A, Stephens AD, Anthony Stuart O, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55(2):130–138.
    1. Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Diseases of the Colon and Rectum. 2000;43(10):1341–1348.
    1. Tentes AA. Preliminary results with the use of hyperthermic intraoperative intraperitoneal chemotherapy or systemic chemotherapy in high-risk colorectal cancer patients. Translational Gastrointestinal Cancer. 2013;2(1)
    1. Noura S, Ohue M, Shingai T, et al. Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings. Annals of Surgical Oncology. 2011;18(2):396–404.
    1. Braam HJ, Boerma D, Wiezer MJ, Ramshorst V. Hyperthermic intraperitoneal chemotherapy during primary tumour resection limits extent of bowel resection compared to two-stage treatment. European Journal of Surgical Oncology. 2013;39:988–993.
    1. Sammartino P, Sibio S, Accarpio F, di Giorgio A. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases
    1. Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World Journal of Surgery. 2001;25(8):985–990.
    1. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. Journal of Clinical Oncology. 2004;22(16):3284–3292.
    1. Griffen WO, Jr., Humphrey L, Sosin H. The prognosis and management of recurrent abdominal malignancies. Current Problems in Surgery. 1969:3–41.
    1. Minton JP, Hoehn JL, Gerber DM, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer. 1985;55(6):1284–1290.
    1. Sugarbaker PH. Second-look surgery for colorectal cancer: revised selection factors and new treatment options for greater success. International Journal of Surgical Oncology. 2011;2011:8 pages.915078
    1. Elias D, Goéré D, di Pietrantonio D, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Annals of Surgery. 2008;247(3):445–450.
    1. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. Journal of Clinical Oncology. 2009;27(5):681–685.
    1. Delhorme JB, Triki E, Zeca I, et al. Mandatory second-look surgery after surgical treatment of peritoneal carcinomatosis of colonic origin
    1. Kuramoto M, Shimada S, Ikeshima S, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Annals of Surgery. 2009;250(2):242–246.
    1. Sugarbaker PH. An overview of peritonectomy, visceral resections, and perioperative chemotherapy for peritoneal surface malignancy. In: Sugarbaker PH, editor. Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas. Woodbury, NY, USA: Cine-Med Publishing; 2012. pp. 1–30.
    1. Sugarbaker PH, van der Speeten K, Stuart OA, Chang D, Mahteme H. Patient- and treatment-related variables, adverse events and their statistical relationship for treatment of peritoneal metastases. In: Sugarbaker PH, editor. Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas. Woodbury, NY, USA: Cine-Med Publishing; 2012. pp. 183–206.
    1. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Annals of Surgery. 1995;221(2):124–132.
    1. Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FAN. Long-term survival of peritoneal carcinomatosis of colorectal origin. Annals of Surgical Oncology. 2005;12(1):65–71.
    1. Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Annals of Surgical Oncology. 2004;11(2):178–186.
    1. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric french study. Journal of Clinical Oncology. 2010;28(1):63–68.
    1. Kuijpers AM, Mirck B, Aalbers AG, et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Annals of Surgical Oncology. 2013;20(13):4224–4230.
    1. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. Journal of Clinical Oncology. 2003;21(20):3737–3743.
    1. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Annals of Surgical Oncology. 2008;15(9):2426–2432.
    1. Sugarbaker PH. Achieving long-term survival with cytoreductive surgery and perioperative chemotherapy to peritoneal surfaces for metastatic colon cancer. American Society of Clinical Oncology. 2011
    1. Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ., III Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756–3762.
    1. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. Journal of Clinical Oncology. 2009;27(5):681–685.
    1. Baumann K, Pfisterer J, Wimberger P, et al. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology. 2011;123(1):27–32.
    1. van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacology of perioperative cancer chemotherapy. In: Sugarbaker PH, editor. Cytoreductive Surgery and Perioperative Chemotherapy for Peritoneal Surface Malignancy: Textbook and Video Atlas. Woodbury, NY, USA: Cine-Med Publishing; 2012. pp. 183–206.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever